Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 28-Jan-2021 16:14:31

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • GP Practices
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: COVID-19 Therapeutic Alert - Antimicrobials (azithromycin and doxycycline) Not Beneficial in the Management of COVID-19 (SARS-CoV-2) Positive Patients

Broadcast content: The recent announcement from the National Institute for Health Research (NIHR) supported PRINCIPLE trial demonstrates the vital importance of robust clinical trials in our response to COVID-19. The lack of beneficial effect in patients aged over 50 who are treated with either azithromycin or doxycycline at home in the early stages of COVID-19 suggests that these antibiotics should not be used within primary care for the treatment of COVID-19 unless there is an additional licensed indication. Overuse of antibiotics in the community can contribute to antimicrobial resistance.

Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy.

Alert reference: CEM/CMO/2021/003


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency